Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Yulian Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4090-0551; OpenAlex author ID A5012987620. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 1, last author 25)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 8 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers, 1 trial · 2025: 2 papers · 2026: 2 papers

Papers 37

  1. Noninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41746-025-02303-9↗
  2. Palmaturbine Inhibits Pancreatic Ductal Adenocarcinoma by Suppressing the JAK2/STAT3 Signaling Pathway. Last author DOI 10.3390/ijms27041707↗
  3. Unraveling the Role of MDK-SDC4 Interaction in Pancreatic Cancer-Associated New-Onset Diabetes by Single-Cell Transcriptomic Analysis. Last author DOI 10.1002/advs.202409987↗
  4. IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC. Co-author DOI 10.1016/j.celrep.2025.116476↗
  5. Predicting Pancreatic Cancer in New-Onset Diabetes Cohort Using a Novel Model With Integrated Clinical and Genetic Indicators: A Large-Scale Prospective Cohort… Last author DOI 10.1002/cam4.70388↗
  6. Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5. Last author DOI 10.1038/s12276-024-01346-4↗
  7. Author Correction: Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL… Last author DOI 10.1038/s12276-024-01363-3↗
  8. Development and Application of a Novel Machine Learning Model Predicting Pancreatic Cancer-Specific Mortality. Last author DOI 10.7759/cureus.57161↗
  9. Elderly Pancreatic Adenocarcinoma Cancer Patients Could Benefit From Postoperative Chemotherapy. Co-author DOI 10.1097/mpa.0000000000002214↗
  10. Prediction of risk and overall survival of pancreatic cancer from blood soluble immune checkpoint-related proteins. Co-author DOI 10.3389/fimmu.2023.1189161↗
  11. Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography. Co-author DOI 10.1016/j.eclinm.2021.101215↗
  12. O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REGγ interaction. Last author DOI 10.1038/s41418-022-00984-3↗
  13. Multi-institutional development and external validation of machine learning-based models to predict relapse risk of pancreatic ductal adenocarcinoma after radi… Last author DOI 10.1186/s12967-021-02955-7↗
  14. Exosomes Derived from Pancreatic Cancer Cells Induce Osteoclast Differentiation Through the miR125a-5p/TNFRSF1B Pathway. Last author DOI 10.2147/ott.s282319↗
  15. A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implicati… Co-author DOI 10.3389/fcell.2021.619549↗
  16. An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2021.665161↗
  17. A Novel Ferroptosis-Related Gene Signature Predicts Recurrence in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.650264↗
  18. Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.659168↗
  19. Development and Validation of a 7-Gene Prognostic Signature to Improve Survival Prediction in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fmolb.2021.676291↗
  20. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matchi… Last author DOI 10.3724/zdxbyxb-2021-0194↗
  21. FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Last author DOI 10.18632/aging.102564↗
  22. A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth. Last author DOI 10.2147/ott.s246969↗
  23. Pancreatic cancer-derived exosomes promoted pancreatic stellate cells recruitment by pancreatic cancer. Last author DOI 10.7150/jca.27590↗
  24. Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2018.01.026↗
  25. Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1 cells in vitro by down-regulating the PCSK1/3. Last author DOI 10.1016/j.canlet.2018.05.027↗
  26. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy. Co-author DOI 10.1021/acsnano.6b05541↗
  27. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway. Last author DOI 10.1038/s41598-017-05541-4↗
  28. VNN1, a potential biomarker for pancreatic cancer-associated new-onset diabetes, aggravates paraneoplastic islet dysfunction by increasing oxidative stress. Last author DOI 10.1016/j.canlet.2015.12.031↗
  29. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Last author DOI 10.1016/j.pan.2015.11.007↗
  30. Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway. Last author DOI 10.3892/ol.2016.4928↗
  31. Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling. First author DOI 10.1002/ar.22897↗
  32. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Last author DOI 10.1016/j.canlet.2012.11.015↗
  33. Ten cancer associated genes identified in peripheral blood mononuclear cells from patients with pancreatic adenocarcinoma. Last author DOI 10.5754/hge12766↗
  34. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer. Last author DOI 10.1007/s00432-012-1205-3↗
  35. Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer. Last author DOI 10.3892/ol.2012.783↗
  36. MACC1: A potential molecule associated with pancreatic cancer metastasis and chemoresistance. Last author DOI 10.3892/ol.2012.784↗
  37. Increased expression level of Olfactomedin4 in peripheral blood mononuclear cells of pancreatic adenocarcinoma patients. Last author DOI 10.5754/hge10623↗

Trials 1

  1. Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis Principal investigator NCT06760234↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiawei Li · 8 shared papers, 2021–2025 · strength 1.47
  2. Zengyu Feng · 8 shared papers, 2021–2025 · strength 1.40
  3. Yongji Sun · 4 shared papers, 2024 · strength 0.84
  4. Yiqun Fan · 5 shared papers, 2021–2026 · strength 0.83
  5. Yizhao Zhou · 7 shared papers, 2018–2024 · strength 0.81
  6. Kexian Li · 5 shared papers, 2021 · strength 0.79
  7. Chenghong Peng · 5 shared papers, 2021 · strength 0.79
  8. Jiali Gong · 4 shared papers, 2022–2025 · strength 0.77
  9. Hongxia Xu · 4 shared papers, 2024–2026 · strength 0.76
  10. Xin Dong · 4 shared papers, 2013–2025 · strength 0.65
  11. Muxing Kang · 10 shared papers, 2012–2019 · strength 0.57
  12. Qiaojun He · 3 shared papers, 2024–2025 · strength 0.55
  13. Dongchao Xu · 1 shared paper, 2026 · strength 0.43
  14. Hongzhang Shen · 1 shared paper, 2026 · strength 0.43
  15. Xiaoman He · 3 shared papers, 2019–2022 · strength 0.37
  16. Wenjie Lu · 3 shared papers, 2012–2023 · strength 0.34
  17. Pengping Li · 4 shared papers, 2018–2020 · strength 0.33
  18. Wenjie Qin · 4 shared papers, 2016–2017 · strength 0.28
  19. Lei Zheng · 2 shared papers, 2020–2022 · strength 0.28
  20. Bin Xu · 2 shared papers, 2013–2023 · strength 0.27
  21. Yuefeng Zhang · 3 shared papers, 2017–2020 · strength 0.24
  22. Yi Zhu · 2 shared papers, 2020–2021 · strength 0.24
  23. Xiawei Li · 1 shared paper, 2026 · strength 0.24
  24. Qingqu Guo · 5 shared papers, 2012–2018 · strength 0.23
  25. Jinbo SHI · 1 shared paper, 2021 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.